Clinical trials: Advanced Hepatocellular Carcinoma (HCC)
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
This phase I trial is studying the side effects and best dose of cixutumumab when given together with sorafenib tosylate in treating patients with advanced liver cancer.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma
- Trial name
- NCT01008566
- Testing
- Cixutumumab, Laboratory Biomarker Analysis, Sorafenib Tosylate
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Hepatocellular Carcinoma
Concurrent Nivolumab and External Beam Radiation Therapy for Patients With Advanced HCC
To investigate the efficacy and safety of nivolumab for patients with advanced HCC undergoing EBRT
- Trial name
- Nextrah (NCT04611165)
- Testing
- Nivolumab
- Where
- South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Cancer Center, Korea
Hepatocellular Carcinoma
Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma
This is a phase II study of axitinib as the second-line on the treatment of advanced hepatocellular carcinoma (HCC). The purpose of this study is a proof-of-concept study to see if axitinib has any anti-tumor effect in HCC.
- Trial name
- NCT01273662
- Testing
- AG-013736
- Where
- 3 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- National Taiwan University Hospital
Hepatocellular Carcinoma
SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma
The purpose of the study is to assess the safety and effectiveness of SCT-I10A in combination with SCT510 in patients with HCC who have not received prior systemic therapy.
- Trial name
- HCC (NCT04560894)
- Testing
- SCT-I10A, SCT510, Sorafenib 200mg
- Where
- China
- Volunteers
- 405 people
- Sponsor
- Sinocelltech Ltd.
Hepatocellular Carcinoma
JS207 Combined With JS007 as First-line Treatment for Advanced Hepatocellular Carcinoma
This open-label, multicenter phase II study was designed to evaluate the safety and efficacy of JS207 alone or in combination with JS007 as first-line treatment in subjects with advanced HCC.
- Trial name
- NCT06954467
- Testing
- JS207, JS007
- Where
- 12 sites in China
- Volunteers
- 72 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Recurrent Hepatocellular Carcinoma, Refractory Liver Carcinoma
IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer
This phase Ib trial studies the side effects and best dose of IRX-2 when given together with cyclophosphamide and nivolumab in treating patients with liver cancer that has come back or spread to other parts of the body and does…
- Conditions
- Recurrent Hepatocellular Carcinoma, Refractory Liver Carcinoma, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT03655002
- Testing
- Cyclophosphamide, Cytokine-based Biologic Agent IRX-2, Nivolumab
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- City of Hope Medical Center
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
Hepatocellular carcinoma (HCC) with main trunk portal vein tumor thrombus (PVTT) has poor prognosis. The main lethiferous factor is the upper gastrointestinal hemorrhage by PVTT-related portal hypertension, then the second is the…
- Conditions
- Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Systemic Therapy
- Trial name
- NCT06622031
- Testing
- Transjugular intrahepatic portosystemic shunt, Lenvatinib, PD-1 inhibitor
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Hepatocellular
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
The purpose of this study is to evaluate the safety and efficacy of doxorubicin plus sorafenib versus doxorubicin plus placebo in patients with advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT00108953
- Testing
- Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin
- Where
- 28 sites in United States, Argentina and 4 more
- Volunteers
- 96 people
- Sponsor
- Bayer
Hepatocellular Carcinoma
Predictors of Sorafenib Response in HCC
Evaluating the nutrition status of patients with advanced HCC who received sorafenib. Using the pretreatment nutrition status and quality of life as predictors to sorafenib response
- Trial name
- NCT05967429
- Testing
- The neutrophil-to- lymphocyte ratio, Prognostic nutrition index
- Volunteers
- 80 people
- Sponsor
- Sohag University
Advanced Cancer, Angiosarcoma
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
This study is an open-label, Phase 1, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamic (PD) profiles of a novel fragment crystallizable (Fc)-engineered immunoglobulin G1…
- Conditions
- Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer
- Trial name
- NCT03860272
- Testing
- Botensilimab, Balstilimab
- Where
- 18 sites in United States, United Kingdom
- Volunteers
- 499 people
- Sponsor
- Agenus Inc.
Gastric Cancer, Hepatocellular Carcinoma
Exploratory Clinical Study of Apatinib and SHR-1210 in Treating Advanced Hepatocellular Carcinoma or Gastric Cancer
The purpose of this study is to observe and preliminary explore the efficacy and safety of combination of Apatinib and SHR-1210 regimen in treating advanced hepatocellular carcinoma or gastric cancer.
- Trial name
- NCT02942329
- Testing
- apatinib, SHR-1210
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Hepatocellular Carcinoma (HCC)
Atezolizumab, Bevacizumab, and Tocilizumab in Advanced Hepatocellular Carcinoma
This is a Phase 2, open-label, single-arm, multicenter study designed to evaluate the safety and efficacy of atezolizumab, bevacizumab, and tocilizumab in patients with locally advanced, metastatic, and/or unresectable…
- Trial name
- AB-TCZ (NCT07774247)
- Testing
- Atezolizumab, Bevacizumab, Tocilizumab
- Where
- South Korea
- Volunteers
- 51 people
- Sponsor
- CHA University
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
Hepatocellular Carcinoma
Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy
Patients with advanced HCC, refractory to atezolizumab and bevacizumab /IO-based therapy will be treated with pembrolizumab and lenvatinib.
- Trial name
- NCT05101629
- Testing
- Pembrolizumab, Lenvatinib Capsules
- Where
- 12 sites in Germany
- Volunteers
- 32 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Hepatocellular Carcinoma
Comparison of TACE Versus TACE/TACI Combination in Advanced Hepatocellular Carcinoma With Portal Vein Invasion
The aim of this study is to compare the efficacy of transarterial chemoembolization with adriamycin to transarterial chemoembolization with adriamycin/transarterial chemoinfusion with cisplatin combination in advanced…
- Trial name
- NCT01857726
- Testing
- Doxorubicin, Cisplatin
- Where
- South Korea
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma, Anti-PD1 Antibody
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
For the advanced hepatocellular carcinoma (HCC), the targeted therapy and immunotherapy are recommended. This study focused on the management of Lenvatinib combined anti-PD1 antibody for the HCC.
- Conditions
- Hepatocellular Carcinoma, Anti-PD1 Antibody, Liver Diseases
- Trial name
- NCT04627012
- Testing
- Lenvatinib, Opdivo, Camrelizumab
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Sun Yat-sen University
Carcinoma, Hepatocellular
A Study of Nivolumab and Relatlimab in Combination With Bevacizumab in Advanced Liver Cancer
The purpose of this study is to evaluate the safety and effectiveness of triplet therapy of nivolumab, relatlimab and bevacizumab versus nivolumab and bevacizumab in participants with untreated advanced/metastatic hepatocellular…
- Trial name
- RELATIVITY-106 (NCT05337137)
- Testing
- Relatlimab, Nivolumab, Bevacizumab
- Where
- 61 sites in United States, Australia and 13 more
- Volunteers
- 82 people
- Sponsor
- Bristol-Myers Squibb
CRC, HCC
A Trial of SHR-1210 in Combination With SHR6390 in Patients With Advanced CRC, NSCLC and HCC
This is a Phase Ib/II , Open-label , Investigator-initiated Trail of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With SHR6390 (a CDK4/6 Inhibitor) in Patients With Advanced Colorectal Cancer, Non-small Cell Lung Cancer and…
- Conditions
- CRC, HCC, NSCLC
- Trial name
- NCT03601598
- Testing
- SHR-1210, SHR6390
- Volunteers
- 41 people
- Sponsor
- Harbin Medical University
Hepatocellulcar Carcinoma
Efficacy and Safety Comparison Between PD-1 Inhibitor Combined With Lenvatinib or With Regorafenib For UHCC After Failure of First-line Treatment
There is no definitive evidence regarding the therapeutic efficacy of PD-1 inhibitors combined with tyrosine kinase inhibitors (TKIs) after disease progression following first-line treatment with bevacizumab plus sintilimab for…
- Trial name
- NCT07537985
- Testing
- Lenvatinib, Regorafenib, PD-1 Inhibitor
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Hepatitis B Virus Infection
Inhibition of HBV Replication and Biological Reversal of Cirrhosis (F3-F4) and HCC by Flavonoids
SB Flavonoids for Advanced Liver Disease ManagementSB Flavonoids represents a multi-target therapeutic composition engineered for the comprehensive management of Hepatitis (Acute and Chronic), Advanced Cirrhosis (F3)-(F4), and…
- Trial name
- Flavonoids (NCT07084948)
- Testing
- Flavonoid, Tenofovir
- Where
- 2 sites in United States, Vietnam
- Volunteers
- 134 people
- Sponsor
- Trieu, Nguyen Thi, M.D.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.